MARKET

CEMI

CEMI

Chembio
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.670
+0.020
+0.75%
Pre Market: 2.660 -0.01 -0.37% 09:06 09/24 EDT
OPEN
2.670
PREV CLOSE
2.650
HIGH
2.680
LOW
2.620
VOLUME
3.41K
TURNOVER
--
52 WEEK HIGH
8.75
52 WEEK LOW
2.060
MARKET CAP
76.42M
P/E (TTM)
-2.0520
1D
5D
1M
3M
1Y
5Y
BRIEF-Chembio Reports EUA Submission for DPP Respiratory Antigen Panel
reuters.com · 2d ago
Chembio Announces EUA Submission for DPP Respiratory Antigen Panel
Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today announced the submission of an Emergency Use Authorization (EUA) application to the Food and Drug Administration (FDA) for the compa...
GlobeNewswire · 2d ago
Demand for Disinfectant Products Continues to Grow Despite the Containment of the Pandemic
/PRNewswire/ -- The economy has shown signs of recovery, but fears related to the pandemic and its new variants remain. Last year, the World Health Organization (WHO) published a list of medical devices required, broken down into several categories includi...
PR Newswire - PRF · 3d ago
Chembio Diagnostic Tweets 'Biden has announced a new plan for COVID-19 Employers with 100+ workers will now require vaccines or weekly testing Chembio provides tests for Symptomatic & Asymptomatic serial testing, as well as multiplex COVID/Flu testing'
https://twitter.com/ChembioDx/status/1438881607415472128?s=20
Benzinga · 6d ago
An Innovative Approach is Needed to Manage a Growing Demand for Medical Supplies
/PRNewswire/ --A hospital's need for medical equipment and supplies is been influenced by several major factors. These include an aging population, increasing occurrences of infectious diseases, methods such as frequent glove swapping and double gloving du...
PR Newswire - PRF · 09/14 13:00
CEI, CEMI and CBIO among pre market gainers
IVERIC bio (NASDAQ:ISEE) +65% Apellis' mixed eye-drug data turns out to be 'positive' for Iveric Bio Vince Holding (NYSE:VNCE) +22% on Q2 earnings. Affirm Holdings (NASDAQ:AFRM) +21% on Q4 earnings. Endo International (NASDAQ:ENDP) +18% settles New
Seekingalpha · 09/10 12:16
20 Stocks Moving in Friday's Pre-Market Session
Gainers IVERIC bio, Inc. (NASDAQ: ISEE) rose 29.6% to $11.26 in pre-market trading. Iveric Bio recently reported inducement grants under Nasdaq Listing Rule 5635(c)(4).
Benzinga · 09/10 11:02
Powerful Software Plays a key Role in Keeping the Pandemic at Bay
/PRNewswire/ -- The pandemic has helped to increase awareness of the importance of maintaining hygiene to avoid transmission of pathogens in healthcare facilities and among the general populous. According to data provided by , the global personal protectiv...
PR Newswire - PRF · 09/08 13:00
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of CEMI. Analyze the recent business situations of Chembio through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 3 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average CEMI stock price target is 8.00 with a high estimate of 8.00 and a low estimate of 8.00.
EPS
Institutional Holdings
Institutions: 104
Institutional Holdings: 6.64M
% Owned: 23.20%
Shares Outstanding: 28.62M
TypeInstitutionsShares
Increased
6
330.53K
New
13
515.87K
Decreased
32
2.05M
Sold Out
25
921.46K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
+0.99%
Pharmaceuticals & Medical Research
+1.27%
Key Executives
Chairman/Executive Director
Gail Page
Non-Executive Chairman/Independent Director
Katherine Davis
President/Chief Executive Officer/Director
Richard Eberly
Chief Financial Officer/Executive Vice President
Neil Goldman
Executive Vice President/Chief Technology Officer/Chief Scientific Officer
Javan Esfandiari
Independent Director
David Acheson
Independent Director
David Bespalko
Independent Director
John Potthoff
No Data
  • All
  • Financials
  • Insiders
More
About CEMI
Chembio Diagnostics, Inc. is a provider of point-of-care diagnostic products for the detection and diagnosis of infectious diseases. The Company is primarily focused on expanding its product portfolio based upon its Dual Path Platform (DPP). The Company's products include rapid tests for the detection of human immunodeficiency virus (HIV) 1/2 antibodies, and a multiplex rapid test for the detection of HIV and Syphilis antibodies. The Company’s point-of-care infectious disease portfolio is comprised of multiple commercial products and are performed with a tiny drop of blood from the fingertip and provide results in approximately 15 minutes. The Company’s products include DPP HIV 1/2, DPP HIV-Syphilis, DPP Syphilis Screen and Confirm, DPP Zika, DPP Leishmaniasis, STAT-PAK HIV 1/2, STAT-PAK Chagas, SURE CHECK HIV 1/2 and SURE CHECK HIV 1/2 Self- Test.

Webull offers kinds of Chembio Diagnostics Inc stock information, including NASDAQ:CEMI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CEMI stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CEMI stock methods without spending real money on the virtual paper trading platform.